pharma

Given therapeutics in the cancer category dominate the list is not so surprising, given the hefty price tag they yield. Where there is a great return there tends to be a great investment.
The pharmaceutical industry does not make a move without knowing what is coming down the pike, or without global projections years into the future. This latest maneuver is standard fare.